Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2014

01-07-2014 | Research Article

Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies

Published in: Tumor Biology | Issue 7/2014

Login to get access

Abstract

Prostate cancer (PC) is the more frequently diagnosed neoplasia in men in developed countries. The evolution of PC to castration-resistant prostate cancer (CRPC) represents real problems of clinical management, in consequence to the limited therapeutic options. MicroRNAs (miRNAs) are small noncoding RNAs that play an important role in gene expression and function regulation. The increased evidence that miRNAs are involved in cancer development and progression has made them potential biomarkers for cancer diagnosis, prognosis, and aggressiveness. Our purpose was to identify a miRNA expression profile associated with the development of CRPC. We firstly observed a miRNA expression profile differentially expressed between the castration-resistant (CR) PC3 cell line and the hormone-sensitive LnCaP cell line, where miR-7, miR-221, and miR-222 were upregulated in PC3 (11.3-fold increase, P = 0.012; 11.3-fold increase, P = 0.002; 8.6-fold increase, P = 0.002, respectively). We also observed that the trend of miR-1233 expression levels was higher in PC3 (3.7-fold increase, P = 0.057). These miRNAs differentially expressed in vitro were studied in a peripheral whole-blood samples from PC patients. We observed that patients presenting an early CR acquisition (≤20 months) had higher expression levels of miR-7 and miR-221 (P = 0.034 and P = 0.036, respectively). Furthermore, we found that patients diagnosed with high-Gleason score tumors and presenting simultaneous higher miR-7 expression levels have a significant reduce time to CR compared with patients who present lower miR-7 expression levels (11 vs. 51 months, log-rank test P = 0.004). We also found that patients diagnosed with high-Gleason score tumors and higher expression levels of miR-221 have an early CRPC compared to patients with lower miR-221 expression levels (10 vs. 46 months, log-rank test P = 0.012). We observed a significantly lower overall survival in patients with higher peripheral whole-blood expression levels of miR-7 (28 vs. 116 months, log-rank test P = 0.001). Our results suggest that miR-7 and miR-221 peripheral whole-blood expression levels can be potential predictive biomarkers of CRPC development.
Literature
1.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–92.CrossRefPubMed
2.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.CrossRefPubMed
3.
Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, et al. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol. 2013;138:248–56.PubMedCentralCrossRefPubMed
4.
Attar RM, Takimoto CH, Gottardis MM. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15:3251–5.CrossRef
5.
6.
Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45.CrossRefPubMed
7.
Hessvik NP, Sandvig K, Llorente A: Exosomal miRNAs as biomarkers for prostate cancer. Frontiers in genetics 2013;4
8.
Zhu KC, Lu JJ, Xu XL, Sun JM. MicroRNAs in androgen-dependent PCA. Front Biosci. 2013;18:748–55.CrossRef
9.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.PubMedCentralCrossRefPubMed
10.
Szczyrba J, Loprich E, Wach S, Jung V, Unteregger G, Barth S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res: MCR. 2010;8:529–38.CrossRefPubMed
11.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469–77.PubMedCentralCrossRefPubMed
12.
Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem. 2007;282:23716–24.CrossRefPubMed
13.
Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells. 2009;27:1712–21.PubMedCentralCrossRefPubMed
14.
Cho WCS. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol. 2010;42:1273–81.CrossRefPubMed
15.
16.
Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011;4:ra41.CrossRefPubMed
17.
Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, Spoerke J, Jhunjhunwala S, Boyd Z, Januario T, Newman RJ, Yue P, Bourgon R, Modrusan Z, Stern HM, Warming S, de Sauvage FJ, Amler L, Yeh RF, Dornan D: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Science signaling 2011;4:pt5
18.
Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA. Farace MG: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1. J Biol Chem. 2007;282:23716–24.CrossRefPubMed
19.
20.
Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.PubMedCentralCrossRefPubMed
21.
Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.CrossRefPubMed
22.
Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocrine-Related Cancer. 2013;20:R83–99.CrossRefPubMed
23.
Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22.PubMedCentralCrossRefPubMed
24.
Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Transatlantic Prostate G: molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer. 2010;102:678–84.PubMedCentralCrossRefPubMed
25.
Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mtor kinase in endometrioid endometrial carcinoma. BMC Cancer. 2012;12:369.PubMedCentralCrossRefPubMed
26.
Watanabe R, Wei L, Huang J. mTOR signaling, function, novel inhibitors, and therapeutic targets. J Nucl Med: Off Publ Soc Nucl Med. 2011;52:497–500.
27.
Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One. 2011;6:e25787.PubMedCentralCrossRefPubMed
28.
Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38:1093–101.PubMed
29.
30.
Teixeira AL, Ribeiro R, Morais A, Lobo F, Fraga A, Pina F, et al. Combined analysis of EGF+61G>A and TGFB1+869T>C functional polymorphisms in the time to androgen independence and prostate cancer susceptibility. Pharmacogenomics J. 2009;9:341–6.CrossRefPubMed
31.
Gan Y, Shi C, Inge L, Hibner M, Balducci J, Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene. 2010;29:4947–58.CrossRefPubMed
32.
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2002;8:3438–44.
33.
Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101:1949–56.PubMedCentralCrossRefPubMed
34.
Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem. 2004;279:7119–30.CrossRefPubMed
35.
Zhang J, Zhao H, Gao Y, Zhang W. Secretory miRNArnas as novel cancer biomarkers. Biochim Biophys Acta. 1826;2012:32–43.
36.
37.
38.
39.
40.
Nana-Sinkam SP, Croce CM. MicroRNArnas as therapeutic targets in cancer. Transl Res. 2011;157:216–25.CrossRefPubMed
41.
Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E, et al. Role of microRNArnas in endothelial cell pathophysiology. Pol Arch Med Wewn. 2011;121:361–6.PubMed
42.
Carlsson J, Helenius G, Karlsson MG, Andren O, Klinga-Levan K, Olsson B. Differences in microRNArna expression during tumor development in the transition and peripheral zones of the prostate. BMC Cancer. 2013;13:362.PubMedCentralCrossRefPubMed
43.
Lorenzen JM, Thum T. Circulating and urinary microRNArnas in kidney disease. Clin J Am Soc Nephrol: CJASN. 2012;7:1528–33.CrossRefPubMed
44.
45.
Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNArnas: nNew biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41:1897–912.PubMed
46.
Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNArnas are correlated with tumor progression in prostate cancer. Int J Cancer J Int Cancer. 2011;128:608–16.CrossRef
47.
Lewis H, Lance R, Troyer D, Beydoun H, Hadley M, Orians J, Benzine T, Madric K, Semmes OJ, Drake R, Esquela-Kerscher A: mMiRr-888 is an expressed prostatic secretions-derived microRNArna that promotes prostate cell growth and migration. Cell cycle 2013;13.
48.
Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, et al. Keratinization-associated miRr-7 and miRr-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECkreck) in oral cancer. J Biol Chem. 2012;287:29261–72.PubMedCentralCrossRefPubMed
49.
Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, et al. Liposomal delivery of microRNArna-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther. 2011;10:1720–7.CrossRefPubMed
50.
Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, et al. Identification of miRr-7 as an oncogene in renal cell carcinoma. J Mol Histol. 2013;44:669–77.CrossRefPubMed
51.
Teixeira AL, Gomes M, Medeiros R. Egfr signaling pathway and related-miRNArnas in age-related diseases: tThe example of miRr-221 and miRr-222. Front Genet. 2012;3:286.PubMedCentralCrossRefPubMed
52.
Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL, et al. MicroRNArna-221/222 confers tamoxifen resistance in breast cancer by targeting p27kip1. J Biol Chem. 2008;283:29897–903.PubMedCentralCrossRefPubMed
53.
Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miRr-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010;25:1674–80.CrossRefPubMed
54.
Li W, Guo F, Wang P, Hong S, Zhang C. mMiRr-221/222 confers radioresistance in glioblastoma cells through activating Aakt independent of PTENpten status. Curr Mol Med. 2014;14:185–95.CrossRefPubMed
55.
Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, et al. MicroRNArna-221 and microRNArna-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTENpten. BMC Cancer. 2010;10:367.PubMedCentralCrossRefPubMed
56.
Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Mauricio J, Lobo F, Medeiros R: Higher circulating expression levels of miRr-221 associated with poor overall survival in renal cell carcinoma patients. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2013.
57.
Dias F, Teixeira AL, Santos JI, Gomes M, Nogueira A, Assis J, et al. Renal cell carcinoma development and miRNArnas: A a possible link to the EGFRegfr pathway. Pharmacogenomics. 2013;14:1793–803.CrossRefPubMed
58.
Di Lorenzo G, Autorino R, De Laurentiis M, Cindolo L, D'Armiento M, Bianco AR, et al. HERer-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori. 2004;90:163–70.PubMed
Metadata
Title
Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies
Publication date
01-07-2014
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1918-9

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue

Research Article

HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

Editorial

In memory of Garry Abelev 1928–2013

Research Article

miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1

Research Article

Association between the SULT1A1 Arg213His polymorphism and the risk of bladder cancer: a meta-analysis

Research Article

CD 152 gene polymorphisms and risk of osteosarcoma in Chinese population

Research Article

EphB4 regulates the growth and migration of pancreatic cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits